Related Experiment Videos
Niflumic acid and cutaneous reactions in children
F Menniti-Ippolito1, L Sagliocca, R Da Cas
1Department of Epidemiology and Biostatistics, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy. fmenniti@iss.it
Insights
Niflumic acid significantly increases the risk of serious mucocutaneous events in children, with an odds ratio of 4.9. Safer alternatives exist, making this drug
Area of Science:
- Pediatric pharmacology
- Drug safety
- Clinical toxicology
Background:
- Adverse drug reactions (ADRs) pose a significant risk in pediatric populations.
- Identifying specific drug risks is crucial for patient safety.
- Mucocutaneous events are severe adverse reactions requiring careful monitoring.
Purpose of the Study:
- To investigate the association between niflumic acid use and serious mucocutaneous events in children.
- To quantify the risk of these events associated with niflumic acid.
- To provide evidence-based recommendations regarding niflumic acid prescription in pediatric care.
Main Methods:
- A case control study design was employed.
- Data on drug use and adverse events were collected and analyzed.
- Statistical analysis, including odds ratio calculation and confidence intervals, was performed.
Main Results:
- An adjusted odds ratio of 4.9 (95% CI 1.9 to 12.8) was found for serious mucocutaneous events in niflumic acid users.
- This indicates a statistically significant increased risk associated with niflumic acid.
- Concomitant drug use was adjusted for in the analysis.
Conclusions:
- Niflumic acid is associated with a substantially increased risk of serious mucocutaneous events in children.
- The availability of safer analgesic and antipyretic options suggests that niflumic acid should be avoided.
- Healthcare providers should prioritize safer alternatives for pediatric pain and fever management.
Abstract:
In a case control study of adverse drug reactions in children, the odds ratio of developing a serious mucocutaneous event among users of niflumic acid, adjusted for concomitant use of all other drugs, was 4.9 (95% CI 1.9 to 12.8). Given the availability of safer analgesics and antipyretics, there is no indication, in our opinion, that requires the prescription of substances which bear an increased risk.